JP2024512793A5 - - Google Patents
Info
- Publication number
- JP2024512793A5 JP2024512793A5 JP2023561040A JP2023561040A JP2024512793A5 JP 2024512793 A5 JP2024512793 A5 JP 2024512793A5 JP 2023561040 A JP2023561040 A JP 2023561040A JP 2023561040 A JP2023561040 A JP 2023561040A JP 2024512793 A5 JP2024512793 A5 JP 2024512793A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- ceftibutene
- administered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163170936P | 2021-04-05 | 2021-04-05 | |
| US63/170,936 | 2021-04-05 | ||
| PCT/US2022/071479 WO2022217199A1 (en) | 2021-04-05 | 2022-03-31 | Ceftibuten dosing regimens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024512793A JP2024512793A (ja) | 2024-03-19 |
| JP2024512793A5 true JP2024512793A5 (enExample) | 2025-03-03 |
Family
ID=83545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023561040A Pending JP2024512793A (ja) | 2021-04-05 | 2022-03-31 | セフチブテン投与レジメン |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240197750A1 (enExample) |
| EP (1) | EP4319760A4 (enExample) |
| JP (1) | JP2024512793A (enExample) |
| KR (1) | KR20230167077A (enExample) |
| CN (1) | CN117157078A (enExample) |
| AU (1) | AU2022254114A1 (enExample) |
| BR (1) | BR112023020348A2 (enExample) |
| CA (1) | CA3212788A1 (enExample) |
| MX (1) | MX2023011483A (enExample) |
| TW (1) | TW202304430A (enExample) |
| WO (1) | WO2022217199A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017290060B2 (en) | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| US12636297B2 (en) | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| US12637481B2 (en) | 2020-03-18 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| IL297458A (en) | 2020-05-05 | 2022-12-01 | Qpex Biopharma Inc | Boronic acid derivatives and their synthesis, polymorphic forms and medicinal uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170252351A1 (en) * | 2015-01-24 | 2017-09-07 | Wockhardt Limited | Antibacterial Compositions |
| AU2017290060B2 (en) * | 2016-06-30 | 2021-07-22 | Qpex Biopharma, Inc | Boronic acid derivatives and therapeutic uses thereof |
| AU2017295866A1 (en) * | 2016-07-14 | 2019-01-17 | Achaogen, Inc. | Combination of ceftibuten and clavulanic acid for use in the treatment of bacterial infections |
| SG11201901658PA (en) * | 2016-09-16 | 2019-04-29 | Entasis Therapeutics Ltd | Beta-lactamase inhibitor compounds |
| US10085999B1 (en) * | 2017-05-10 | 2018-10-02 | Arixa Pharmaceuticals, Inc. | Beta-lactamase inhibitors and uses thereof |
| WO2019093450A1 (ja) * | 2017-11-10 | 2019-05-16 | 塩野義製薬株式会社 | ジアザビシクロオクタン誘導体 |
| DK3886798T3 (da) * | 2018-11-29 | 2026-04-20 | Basilea Pharmaceutica Int Ag Allschwil | Kombinationssammensætninger, som omfatter en beta-lactamase-hæmmer, og anvendelser deraf |
| US12636297B2 (en) * | 2019-06-19 | 2026-05-26 | Qpex Biopharma, Inc. | Boronic acid derivatives and therapeutic uses thereof |
| EP4021443A1 (en) * | 2019-08-29 | 2022-07-06 | Arixa Pharmaceuticals, Inc. | Orally administered combinations of beta-lactam antibiotics and avibactam derivatives for treating bacterial infections |
-
2022
- 2022-03-31 EP EP22785621.8A patent/EP4319760A4/en active Pending
- 2022-03-31 US US18/553,769 patent/US20240197750A1/en active Pending
- 2022-03-31 BR BR112023020348A patent/BR112023020348A2/pt unknown
- 2022-03-31 KR KR1020237037971A patent/KR20230167077A/ko not_active Withdrawn
- 2022-03-31 JP JP2023561040A patent/JP2024512793A/ja active Pending
- 2022-03-31 AU AU2022254114A patent/AU2022254114A1/en not_active Abandoned
- 2022-03-31 CA CA3212788A patent/CA3212788A1/en active Pending
- 2022-03-31 WO PCT/US2022/071479 patent/WO2022217199A1/en not_active Ceased
- 2022-03-31 MX MX2023011483A patent/MX2023011483A/es unknown
- 2022-03-31 CN CN202280024764.7A patent/CN117157078A/zh active Pending
- 2022-04-01 TW TW111112897A patent/TW202304430A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2221795C2 (ru) | Имидазолил-циклические ацетали, промежуточные соединения, фармацевтическая композиция и способ лечения | |
| JP2006507326A5 (enExample) | ||
| JP2022545291A5 (enExample) | ||
| JP2023052094A5 (enExample) | ||
| JP2002535323A5 (enExample) | ||
| CN1170584C (zh) | 利用精氨酸衍生物增强噁唑烷酮抗菌剂的活性 | |
| JP2004534774A5 (enExample) | ||
| JP2007522098A5 (enExample) | ||
| JP2010510999A5 (enExample) | ||
| JP5470245B2 (ja) | バイオフィルム形成の処置のためのトリアゾール化合物 | |
| IL205501A (en) | Preparation of preparations for the treatment of arthritis | |
| CA2487542A1 (en) | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides | |
| JP2023533485A5 (enExample) | ||
| JP2011506501A5 (enExample) | ||
| JP2024507414A5 (enExample) | ||
| CA2475619A1 (en) | Piperidine derivatives | |
| US20150132347A1 (en) | Treating inflammatory conditions and improving oral hygiene using metal modulators with methylsulfonylmethane as transport enhancer | |
| Galgiani et al. | Bacteroides fragilis endocarditis, bacteremia and other infections treated with oral or intravenous metronidazole | |
| JP2005527521A5 (enExample) | ||
| JP2008509210A5 (enExample) | ||
| RU2001119914A (ru) | Средство для лечения болезни паркинсона, включающее в качестве активного ингредиента соединение, улучшающее астроцитную функцию | |
| US4148878A (en) | Inhibition of platelet aggregation with selected phosphoric acid esters | |
| JP2003048842A (ja) | 歯垢形成抑制剤 | |
| JP2022511392A5 (enExample) | ||
| CN108685911B (zh) | 2-[(4-叔丁基噻唑-2-基)亚氨基]噻唑啉-4-酮在制药中的应用 |